CN104721843B - Dewatering medicament nano capsule that a kind of pH with near-infrared fluorescent tracer is responded and preparation method thereof - Google Patents
Dewatering medicament nano capsule that a kind of pH with near-infrared fluorescent tracer is responded and preparation method thereof Download PDFInfo
- Publication number
- CN104721843B CN104721843B CN201510174148.1A CN201510174148A CN104721843B CN 104721843 B CN104721843 B CN 104721843B CN 201510174148 A CN201510174148 A CN 201510174148A CN 104721843 B CN104721843 B CN 104721843B
- Authority
- CN
- China
- Prior art keywords
- infrared fluorescent
- nano capsule
- nano
- preparation
- responded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 239000002088 nanocapsule Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000700 radioactive tracer Substances 0.000 title claims abstract description 13
- 239000002105 nanoparticle Substances 0.000 claims abstract description 14
- 230000004044 response Effects 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 229930012538 Paclitaxel Natural products 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 229960001592 paclitaxel Drugs 0.000 claims description 11
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- -1 oleyl amines Chemical class 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 7
- 239000003643 water by type Substances 0.000 claims description 7
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 5
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- GKEMUBZAKCZMKO-UHFFFAOYSA-N ethane-1,2-diol;ethene Chemical compound C=C.OCCO GKEMUBZAKCZMKO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 3
- WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000005284 excitation Effects 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 125000002456 taxol group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 13
- 201000011510 cancer Diseases 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 5
- 230000002209 hydrophobic effect Effects 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 230000008685 targeting Effects 0.000 abstract description 3
- 229910052946 acanthite Inorganic materials 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 239000008346 aqueous phase Substances 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 239000003937 drug carrier Substances 0.000 abstract description 2
- 238000011503 in vivo imaging Methods 0.000 abstract description 2
- FSJWWSXPIWGYKC-UHFFFAOYSA-M silver;silver;sulfanide Chemical compound [SH-].[Ag].[Ag+] FSJWWSXPIWGYKC-UHFFFAOYSA-M 0.000 abstract description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000000799 fluorescence microscopy Methods 0.000 description 5
- 230000032258 transport Effects 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a kind of pH with near-infrared fluorescent tracer for belonging to technical field of nanometer material preparation dewatering medicament nano capsules responded and preparation method thereof, and be applied to in-vivo imaging, treatment of cancer, medicine tracking research in.Present invention synthesis is enclosed with hydrophobic anticancer drug and Ag2S nano particles, pH responses (being degraded in sour environment), the dewatering medicament nano capsule that a diameter of 70 150nm or so the pH with near-infrared fluorescent tracer is responded, dispersiveness is stable in aqueous phase, in the case where 808nm light excites, the stable and strong area's fluorescence of near-infrared two is sent, available for medicine in blood circulation process and its real-time tracing in knub position；Nano capsule preparation method is novel simple in the present invention, compared with the medicament transport carrier reported before, the pharmaceutical carrier has cancer cell targeting, pH response characteristics, can send the area's fluorescence of near-infrared two, fluorescence signal is strong, is identified available for medicine real-time tracing and curative effect.
Description
Technical field
The invention belongs to technical field of nanometer material preparation, more particularly to a kind of dewatering medicament nano capsule of pH responses
The biological medicine application of insoluble drug release and near-infrared fluorescent tracking drug distribution.
Technical background
Medicine tracking is even more important for pharmacokinetic.And real-time tracing of the medicine in vivo in cyclic process is past
Toward the spatial resolution or temporal resolution for being limited to analysis method, fluorescence probe sends visible as using fluorescence imaging
Light, it is difficult to animal tissue is penetrated, and the imaging method gathered data such as Magnetic resonance imaging, CT, B ultrasound needs the long period, not
Real time imagery.And the near infrared fluorescent probe Ag that near-infrared fluorescence imaging method utilizes2S nano particles are that 808nm is closely red in wavelength
Outer light, which excites down, sends the area of near-infrared two (1100-1400nm), can penetrate tissue, and fluorescence imaging in itself can instantaneously into
Picture, the data obtained are real time data, are highly suitable for the real-time tracing of medicine cyclic process in vivo.
Targeting transport and controlled release are particularly important in medicament transport research.Nano medicinal capsule is in itself using tumor group
The high-permeability knitted and high anelasticity, by body-internal-circulation process, accumulated in tumor tissues, be referred to as passive target.Active target
To utilize be Nano capsule surface coupling polypeptide or other tumor cell surface proteins targeted molecular, it is thin with tumour
Medicament capsule is enriched with tumor tissues and discharges medicine during born of the same parents' specific bond.And the controlled release of medicine be then related to it can be
Normal tissue cell is not injured while effectively killing cancer cell, it is most important to mitigating treatment of cancer side effect.
The content of the invention
It is an object of the invention to provide a kind of pH with near-infrared fluorescent tracer dewatering medicament nano capsules responded and its
Preparation method, and be applied to in-vivo imaging, treatment of cancer, medicine tracking research in.
The preparation method for the dewatering medicament nano capsule that pH of the present invention with near-infrared fluorescent tracer is responded, it has
Body step is：
A. 0.2-2.0g polysuccinimides are added in 20-50mL DMF, is heated to 60-120
DEG C keep 1-4 hours until dissolving；Then 0.3-3.0mL oleyl amines are added, are kept for 60-120 DEG C of 4-8 hour；It is eventually adding methanol
Make its precipitation, centrifuge, then precipitation is scattered in 2-10mL chloroforms, obtain oleyl amine grafting polysuccinimide
Chloroform soln；
B. it is 1-10mg poly- (ethene-ethylene glycol), 0.1-1.0mg dewatering medicaments, 50-200 μ L 0.01-0.1mmol/L is near
The chloroform soln of infrared fluorescent material, 200-400 μ L oleyl amines are grafted the chloroform soln of polysuccinimide, 200-
800 μ L chloroforms and 8-15mL deionized waters and the mixing of the 50-100 μ L 0.05-0.2mmol/L NaOH aqueous solution, 200-
Ultrasonic 4-9min under 400W power, obtained emulsion stir 0.5-2.5h evaporation chloroforms at 40-60 DEG C；Reaction terminates
Afterwards, centrifuge washing, product, which is dispersed in 1-5mL deionized waters, obtains Nano capsule solution；
C. 1-10mg 1- (3- dimethylamino-propyls) -3- ethyls are added into Nano capsule solution obtained by 1mL b steps
The target polypeptide of carbodiimide hydrochloride, 1-10mg n-hydroxysuccinimide and 1-10mg, 2-8 hours are stirred under normal temperature,
Centrifuge washing, precipitation are re-dispersed into dredging for the pH responses of i.e. handy near-infrared fluorescent tracer in the phosphate buffer solutions of pH 7.4
Water medicament nano capsule.
Described dewatering medicament is taxol or camptothecine.
Described near-infrared fluorescent material is the Ag of chelated surface oleic acid, oleyl amine or lauryl mercaptan2S nano particles, particle diameter
For 3-10nm, excitation light wave a length of 808nm, wavelength of transmitted light 1100-1400nm.
Described target polypeptide is the peptide chain containing RGD tripeptides.The albumen of recognizable cancer cell surfaces overexpression, can make
Nano capsule orientation transports knub position.
The dewatering medicament nano capsule that the pH with near-infrared fluorescent tracer of above-mentioned synthesis is responded is stable in neutral environment
In the presence of, and degraded in sour environment, medicine can therefrom discharge.
Beneficial effects of the present invention：Present invention synthesis is enclosed with hydrophobic anticancer drug and Ag2S nano particles, pH responses
(being degraded in sour environment), the dewatering medicament nano of a diameter of 70-150nm or so the pH responses with near-infrared fluorescent tracer
Capsule, dispersiveness is stable in aqueous phase, in the case where 808nm light excites, sends the stable and strong area's fluorescence of near-infrared two, can be used for
Medicine is in blood circulation process and its real-time tracing in knub position；Nano capsule preparation method is novel simple in the present invention,
Compared with the medicament transport carrier reported before, the pharmaceutical carrier has cancer cell targeting, pH response characteristics, can send near red
Outer 2nd area fluorescence, fluorescence signal is strong, is identified available for medicine real-time tracing and curative effect.
Brief description of the drawings
Fig. 1 is that the preparation of embodiment 1 is enclosed with taxol and Ag2The TEM photos of the Nano capsule of S nano particles；
Fig. 2 is that the preparation of embodiment 1 is enclosed with taxol and Ag2The Nano capsule of S nano particles is in pH5.0 phosphate-buffereds
TEM photos after being cultivated 24 hours in solution；
Fig. 3 is that embodiment 1 is enclosed with taxol and Ag2The Nano capsule of S nano particles is respectively in pH7.4 and pH5.0 phosphorus
Taxol release ratio changes with time in hydrochlorate cushioning liquid；
Fig. 4 is that embodiment 1 is enclosed with taxol and Ag2The Nano capsule of S nano particles enters Mice Body through tail vein injection
Near-infrared fluorescence imaging figure after interior half an hour, exciting light are 808nm laser；
Fig. 5 is that embodiment 1 is enclosed with taxol and Ag2The Nano capsule of S nano particles enters Mice Body through tail vein injection
Near-infrared fluorescence imaging figure after interior 5 hours, exciting light are 808nm laser；
Fig. 6 is the TEM photos for the Nano capsule that embodiment 2 is enclosed with camptothecine.
Embodiment
Embodiment 1:
A. the preparation method of oleyl amine grafting polysuccinimide：
Kept being heated to 80 DEG C in 1.6g polysuccinimides (PSI) addition 32mL N,N-dimethylformamides for 1 hour
Until dissolving；Then 2.1mL oleyl amines are added, maintain 100 DEG C 4 hours；Being eventually adding methanol makes its precipitation, centrifuges, then
8mL chloroforms are scattered in, obtain the chloroform soln of oleyl amine grafting polysuccinimide；
B. hydrophobic cancer therapy drug and near-infrared fluorescent tracer material are rolled into using oleyl amine grafting polysuccinimide
Nano capsule：
By 5mg poly- (ethene-ethylene glycol), the Ag of 50 μ L 0.05mmol/L chelated surface oleic acid2The trichlorine of S nano particles
Dichloromethane, 200 μ L oleyl amines be grafted polysuccinimide chloroform soln, 1.0mg taxols, 600 μ L chloroforms with
And 10mL deionized waters and the mixing of the 50 μ L 0.1mmol/L NaOH aqueous solution；Ultrasonic 6min under 300W power, obtained emulsion exist
2 hours evaporation chloroforms are stirred at 55 DEG C；After reaction terminates, centrifuge washing, product is dispersed in 5mL deionized waters and received
Rice capsule solution；
C. Nano capsule coupling target polypeptide：
7mg1- (3- dimethylamino-propyls) -3- ethyl carbodiimides are added into Nano capsule solution obtained by 1mL b steps
Hydrochloride EDC, 1mg n-hydroxysuccinimide (NHS) and 1mg contain the peptide chain of RGD tripeptides, are stirred 4 hours under normal temperature, from
The heart is washed, and precipitation is re-dispersed into the phosphate buffer solutions of 1mL pH 7.4.
Taxol and Ag are enclosed with made from step b2The nano medicinal capsule of S nano particles, size are about 70-150nm,
Its TEM photo is as shown in Figure 1.The stably dispersing in deionized water or the phosphate buffer solutions of pH 7.4, in the pH 5.0 of acidity
In phosphate buffer solution, Nano capsule is degraded, and its TEM photo is as shown in Figure 2.Drug taxol can therefrom discharge.Taxol
Release changes over time as shown in Figure 3 in different pH value cushioning liquid.As shown in Figure 4, Figure 5, gained nano medicinal capsule is even
Tumor tissues can be targeted to after the polypeptide of connection identification cancer cell, the Ag in capsule2S nano particles are as fluorescent tracing reagent.
Embodiment 2:
A. the preparation method of oleyl amine grafting polysuccinimide：
Kept being heated to 80 DEG C in 1.6g polysuccinimides (PSI) addition 32mL N,N-dimethylformamides for 1 hour
Until dissolving；Then 2.1mL oleyl amines are added, maintain 100 DEG C 4 hours；Being eventually adding methanol makes its precipitation, centrifuges, then
8mL chloroforms are scattered in, obtain the chloroform soln of oleyl amine grafting polysuccinimide；
B. hydrophobic cancer therapy drug is rolled into Nano capsule using oleyl amine grafting polysuccinimide：
By 5mg poly- (ethene-ethylene glycol), the Ag of 50 μ L 0.05mmol/L chelated surface lauryl mercaptans2S nano particles
Chloroform soln, the chloroform soln of 200 μ L 200mg/mL oleyl amines grafting polysuccinimide, 1.0mg camptothecines, 600
μ L chloroforms and 10mL deionized waters and the mixing of the 50 μ L 0.1mmol/L NaOH aqueous solution；Ultrasonic 6min under 300W power,
Obtained emulsion stirs 2 hours evaporation chloroforms at 55 DEG C；Reaction terminate after, centrifuge washing, product be dispersed in 5mL go from
In sub- water；
C. Nano capsule coupling target polypeptide
7mg1- (3- dimethylamino-propyls) -3- ethyl carbodiimides are added into Nano capsule solution obtained by 1mL b steps
Hydrochloride EDC, 10mg n-hydroxysuccinimide (NHS) and 10mg contain the peptide chain of RGD tripeptides, are stirred 4 hours under normal temperature,
Centrifuge washing, precipitation are re-dispersed into the phosphate buffer solutions of 1mL pH 7.4.
Camptothecine nano medicinal capsule is enclosed with made from step b, size is about 70-150nm, its TEM photo such as Fig. 6 institutes
Show, the stably dispersing in deionization or the phosphate buffer solutions of pH 7.4.
Claims (3)
- A kind of 1. preparation method for the dewatering medicament nano capsule that pH with near-infrared fluorescent tracer is responded, it is characterised in that its Concretely comprise the following steps：A. 0.2-2.0 g polysuccinimides are added in 20-50 mL DMF, is heated to 60-120 DEG C keep 1-4 hours until dissolving；Then 0.3-3.0 mL oleyl amines are added, are kept for 60-120 DEG C of 4-8 hour；It is eventually adding methanol Make its precipitation, centrifuge, then precipitation is scattered in 2-10 mL chloroforms, obtain oleyl amine grafting polysuccinimide Chloroform soln；B. 1-10 mg are gathered（Ethene-ethylene glycol）, 0.1-1.0 mg dewatering medicaments, 50-200 μ L 0.01-0.1 mmol/L The chloroform soln of near-infrared fluorescent material, 200-400 μ L oleyl amines are grafted the chloroform soln of polysuccinimide, 200-800 μ L chloroforms and 8-15 mL deionized waters and the 50-100 μ L 0.05-0.2 mmol/L NaOH aqueous solution mix Close, ultrasonic 4-9 min under 200-400 W power, obtained emulsion stirs 0.5-2.5 h evaporation chloroforms at 40-60 DEG C； After reaction terminates, centrifuge washing, product is dispersed in 1-5 mL deionized waters and obtains Nano capsule solution；C. 1-10 mg 1- (3- dimethylamino-propyls) -3- ethyl carbon is added into Nano capsule solution obtained by 1 mL b steps The target polypeptide of diimmonium salt hydrochlorate, 1-10 mg n-hydroxysuccinimide and 1-10 mg, 2-8 hours are stirred under normal temperature, Centrifuge washing, precipitation are re-dispersed into the pH responses of i.e. handy near-infrared fluorescent tracer in the phosphate buffer solutions of pH 7.4 Dewatering medicament nano capsule；Described dewatering medicament is taxol or camptothecine；Described near-infrared fluorescent material is the Ag of chelated surface oleic acid, oleyl amine or lauryl mercaptan2S nano particles, particle diameter 3- 10 nm, a length of 808 nm of excitation light wave, wavelength of transmitted light are 1100-1400 nm.
- 2. preparation method according to claim 1, it is characterised in that described target polypeptide is the peptide containing RGD tripeptides Chain.
- 3. the dewatering medicament nano that the pH with near-infrared fluorescent tracer that the method according to claim 11 is prepared is responded Capsule, it is characterised in that described dewatering medicament nano capsule is stabilized in neutral environment, and is dropped in sour environment Solution, medicine can therefrom discharge.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510174148.1A CN104721843B (en) | 2015-04-13 | 2015-04-13 | Dewatering medicament nano capsule that a kind of pH with near-infrared fluorescent tracer is responded and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510174148.1A CN104721843B (en) | 2015-04-13 | 2015-04-13 | Dewatering medicament nano capsule that a kind of pH with near-infrared fluorescent tracer is responded and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104721843A CN104721843A (en) | 2015-06-24 |
| CN104721843B true CN104721843B (en) | 2017-11-14 |
Family
ID=53446634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510174148.1A Expired - Fee Related CN104721843B (en) | 2015-04-13 | 2015-04-13 | Dewatering medicament nano capsule that a kind of pH with near-infrared fluorescent tracer is responded and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104721843B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110568184B (en) * | 2019-08-21 | 2022-11-22 | 安徽师范大学 | Fluorescence immunoassay quantitative detection method for anticancer drug camptothecin loaded nano-drug carrier |
| US20230134756A1 (en) * | 2020-03-16 | 2023-05-04 | Firmenich Sa | Microcapsules coated with a polysuccinimide derivative |
| CN111419727A (en) * | 2020-04-22 | 2020-07-17 | 苏州清馨健康科技有限公司 | Anti-inflammatory toothpaste |
| CN115068605B (en) * | 2022-05-23 | 2024-02-23 | 大连民族大学 | Ag (silver) alloy 2 S@TCPP-UiO-66-NH 2 Light response nano antibacterial material, preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104288786B (en) * | 2013-07-17 | 2017-02-22 | 中国科学院苏州纳米技术与纳米仿生研究所 | Tumor targeted diagnosing and treating system based on near-infrared quantum dot and preparation method thereof |
-
2015
- 2015-04-13 CN CN201510174148.1A patent/CN104721843B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| General and Facile Surface Functionalization of Hydrophobic Nanocrystals with Poly(amino acid) for Cell Luminescence Imaging;Sheng Huang et al.;《SCIENTIFIC REPORTS》;20130619;第3卷;第1-5页 * |
| In Vivo Fluorescence Imaging with Ag2S Quantum Dots in the Second Near-Infrared Region;Guosong Hong et al.;《Angew. Chem. Int. Ed.》;20121231;第51卷;第1-5页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104721843A (en) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9393396B2 (en) | Method and composition for hyperthermally treating cells | |
| Jiang et al. | Surface-functionalized nanoparticles for biosensing and imaging-guided therapeutics | |
| Jeong et al. | Photosensitizer-conjugated human serum albumin nanoparticles for effective photodynamic therapy | |
| JP6230443B2 (en) | Near-infrared dye-bound hyaluronic acid derivative and contrast agent for optical imaging having the same | |
| CN104721843B (en) | Dewatering medicament nano capsule that a kind of pH with near-infrared fluorescent tracer is responded and preparation method thereof | |
| KR102081666B1 (en) | Phamaceutical composition for treating cancer | |
| EP1362598A1 (en) | Active oxygen generator containing photosensitizer for ultrasonic therapy | |
| Zhang et al. | pH-driven targeting nanoprobe with dual-responsive drug release for persistent luminescence imaging and chemotherapy of tumor | |
| CN104888217B (en) | Targeted nano light drug for cancer photodynamic therapy | |
| JP2009536151A (en) | Nanoparticles | |
| US20210252171A1 (en) | Magnetic nanoparticles functionalized with catechol, production and use thereof | |
| CN106139144A (en) | A kind of hyaluronic acid decorated golden Nano carbon balls with synergistic antitumor characteristic and preparation method and application | |
| CN102573910A (en) | Targeted nano-photomedicines for photodynamic therapy of cancer | |
| WO2007049708A1 (en) | Ultrasonic cancer therapy accelerator and cytotoxic agent | |
| CN105963717A (en) | Composite nano-drug for integrated tumor diagnosis and treatment and preparation method thereof | |
| CN105251420A (en) | Preparation method for multifunctional composite microspheres | |
| Zhao et al. | Multifunctional magnetic nanoparticles for simultaneous cancer near-infrared imaging and targeting photodynamic therapy | |
| Wang et al. | Functionalization of bismuth sulfide nanomaterials for their application in cancer theranostics | |
| CN103893761B (en) | Tumor cytotoxicity method, system and application of a kind of ultrasonic wave added based on light thermit powder | |
| CN108578696A (en) | A kind of liposome microbubble load metal-ICG self assembly compound systems | |
| CN105641710B (en) | The targeted oxidative graphene of HA/RGD modification is double to carry medicine composite material and preparation method thereof | |
| JP2021514941A (en) | Bilirubin derivative-based diagnostic and therapeutic ultrasound contrast agent | |
| Li et al. | Polydopamine-containing nano-systems for cancer multi-mode diagnoses and therapies: A review | |
| Wang et al. | Recent progress toward imaging application of multifunction sonosensitizers in sonodynamic therapy | |
| US10918718B2 (en) | Sonosensitive therapeutic or diagnostic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171114 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |